SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the treatment of…
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in…